TMCI
Treace Medical Concepts, Inc.
TMCI lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
TMCI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Weak |
TMCI's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
TMCI PE Valuation
TMCI has no meaningful PE right now: it lost money over the past year.
TMCI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect TMCI's losses to shrink, with revenue growing.
TMCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.85 | -$0.05 |
| Q2 2026 | -$0.92 | -$0.13 |
| Q1 2026 | -$0.96 | -$0.11 |
| Q4 2025 | -$0.93 | -$0.03 |
| Q3 2025 | -$0.80 | +$0.19 |
| Q2 2025 | -$0.79 | +$0.23 |
| Q1 2025 | -$0.85 | +$0.03 |
| Q4 2024 | -$0.90 | -$0.09 |
TMCI is still losing money, but less than at its worst: $0.85 per share over the past year, against $1.02 at its worst in mid-2024.
TMCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $48.3M | -3.9% |
| Q2 2026 | $45.4M | -4.2% |
| Q1 2026 | $47.2M | -10% |
| Q4 2025 | $62.5M | -9% |
| Q3 2025 | $50.2M | +11% |
| Q2 2025 | $47.4M | +6.6% |
| Q1 2025 | $52.6M | +2.9% |
| Q4 2024 | $68.7M | +10% |
TMCI's revenue has slid since its 2024 peak: $48M last quarter, down 3.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | +7.3 points |
| Q2 2026 | -33% | +2.9 points |
| Q1 2026 | -36% | -6.7 points |
| Q4 2025 | -9.5% | -9.2 points |
| Q3 2025 | -31% | +2.4 points |
| Q2 2025 | -36% | +12 points |
| Q1 2025 | -30% | +7.5 points |
| Q4 2024 | -0.3% | +11 points |
TMCI's operating margin was −24% last quarter, up 7.3 points from the same quarter a year ago.
TMCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.4M | +$6.5M |
| Q2 2026 | -$6.9M | +$918K |
| Q1 2026 | $4.2M | +538% |
| Q4 2025 | -$10.4M | -$3.1M |
| Q3 2025 | -$11.9M | +$2.8M |
| Q2 2025 | -$7.8M | +$7.8M |
| Q1 2025 | $655K | +$11.8M |
| Q4 2024 | -$7.3M | -$5.6M |
TMCI has burned cash in almost every quarter: −$19M over the past year, against −$26M the year before.
TMCI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +415K shares |
| 1 year | +3.1% | +1.9M shares |
| 3 years | +6.3% | +3.9M shares |
| 5 years | +24% | +12.7M shares |
| Available history | +49% | +21.6M shares |
TMCI has 65M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TMCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | 36.3x | High |
TMCI's net debt is more than 20 years of its operating earnings (EBITDA).
TMCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.8 | Neutral |
| Stochastic | 57.5 | Neutral |
TMCI's weekly RSI is 65 (neutral) and its Stochastic is 58 (neutral).
TMCI PE vs Healthcare Sector
TMCI has no meaningful PE right now: it lost money over the past year.
TMCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.35 | 23% above |
| 20 week MA | $4.41 | 21% above |
| 50 week MA | $3.22 | 66% above |
| 100 week MA | $5.03 | 6.2% above |
| 200 week MA | $9.47 | 44% below |
TMCI has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 44% below its 200-week average.
TMCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.5 | $17.3 | -32% |
| 2022 | $17.3 | $23.9 | +39% |
| 2023 | $23.9 | $12.8 | -47% |
| 2024 | $12.8 | $6.98 | -45% |
| 2025 | $6.98 | $2.42 | -65% |
| 2026 YTD | $2.42 | $5.34 | +121% |
TMCI has finished three years in a row lower, and it's up 121% so far in 2026.